Navigation Links
Synbiotics Corporation Announces Human Submission for FluDetect(R)
Date:3/13/2008

KANSAS CITY, Mo., March 13 /PRNewswire/ -- Synbiotics Corporation today announced that it is seeking 510(k) authorization from the Food & Drug Administration (FDA) for the use of its FluDetect(R) Avian Influenza Virus rapid test strip in humans. This represents Synbiotics first foray into the human point-of-care diagnostic marketplace. While it is not Synbiotics' initial intent to market this product itself to the human field, it is actively seeking an established strategic human diagnostic partner, to market, sell and distribute this product.

Currently, the FluDetect(R) product is the only USDA approved rapid point of care test for avian influenza in the veterinary field. FluDetect(R) has been heralded for its extreme sensitivity in a simple to use test format that requires no equipment, nor extensive training to perform. Management believes this may be the first crossover test to be licensed for use both in humans and animals and can be a vital tool to healthcare institutions for both seasonal flu testing as well as in endemic situations.

"The feedback we have received on the outstanding field performance of FluDetect(R) in avian influenza has encouraged us to seek human use," said Paul Hays, Synbiotics' President & Chief Executive Officer. "It is our goal to find a partner in a timely fashion to be prepared to enter the human market for the 2008-2009 flu season," said Hays. Inquiries by potential partners should be made to Ronan Molloy at ronanm@synbiotics.com.

Synbiotics Corporation develops, manufactures and markets veterinary diagnostic products for the poultry, livestock and companion animal markets worldwide. Synbiotics is an expert in avian influenza surveillance and early detection. Synbiotics manufactures and distributes its products through its operations in San Diego, California, and Lyon, France. For information on Synbiotics and its products, visit the Company's website at http://www.synbiotics.com.

Contacts: Paul Hays

Synbiotics Corporation

1-816-464-3502


'/>"/>
SOURCE Synbiotics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. NanoBio(R) Corporation Completes $30 Million in Equity Funding by Meeting Key Development Milestones
2. Harris Corporation Teams with Cancer Treatment Services International to Advance Oncology Treatment
3. CEL-SCI Corporation Reports First Quarter Financial Results
4. NanoBio Corporation Presents Preclinical and Interim Clinical Data on Topical Treatments for Herpes Labialis and Onychomycosis at AAD 2008
5. Genaera Corporation Presents Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at Keystone Symposia
6. Divine Corporations Personal Lubricants Shown to Block Cancer-causing Viruses in a Study by the National Cancer Institute
7. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
8. Genzyme Corporation Selects Diplomat Specialty Pharmacy for 2008 Renagel Medicare Part D Assistance Program
9. CEL-SCI Corporation Announces 2007 Financial Results
10. Berkery Noyes Represented The Thomson Corporation in the Sale of CenterWatch and New England Institutional Review Board to Jobson Medical Information
11. AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... 2016 Oasmia Pharmaceutical AB ... a new generation of drugs within human and ... for Paclical/Apealea in the Phase III study that ... ovarian cancer. These preliminary results showed non-inferiority between ... carboplatin versus Taxol in combination with carboplatin. In ...
(Date:4/27/2016)... April 27, 2016 At the ... launch of a Phase 2 clinical study of its ... patients undergoing cochlear implantation (CI) surgery. This large, placebo-controlled, ... Germany and France ... ear at the time of surgery. "Despite advances in ...
(Date:4/26/2016)... 26, 2016 US demand for infection ... 4.9 percent annually to $27.6 billion in 2020.  ... to decrease rates of healthcare-associated infections (HAIs) will ... and services.  Although declining, the overall rate of ... levels set by the CDC.  Recent statistics indicate ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 30, 2016 , ... World ... the Pick Up Springboard, an automotive invention that improves the storage features of ... worth $162 billion," says Scott Cooper, CEO and Creative Director of World Patent ...
(Date:4/29/2016)... ... 29, 2016 , ... Since launching its annual volunteer campaign ... the footwear industry, has broken all previous participation records in its first two ... states during the months of April and May, the 2016 Footwear Cares initiative ...
(Date:4/29/2016)... ... , ... Our bodies are bombarded daily by environmental and lifestyle factors that ... is to adopt a more healthful diet, but too many people think that food ... Nutritionist and the creator of the Newport Beach Cleanse and 14-Day Eating Plan, disagrees ...
(Date:4/29/2016)... ... 29, 2016 , ... Dr. Bernie Siegel, (M.D.) ... MEDICINE and MIRACLES") addresses touchy topics related to Death live on Dr. ... Dr. Bernie Siegel, author of a plethora of essential books-to-read for physicians and ...
(Date:4/29/2016)... GA (PRWEB) , ... April 29, 2016 , ... Coast ... May 16, 2016, at its new location in the Exchange Furniture Mall at 112 ... raffle for a 50-inch Samsung Smart TV. Plus attendees will have the opportunity to ...
Breaking Medicine News(10 mins):